This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (545) HIV/AIDS/STI Prevention and Care (879) Consumer & Patient Education and Shared-Decision Making (688)

Published on in Vol 11, No 9 (2022): September

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35646, first published .
A Patient Decision Aid (i.ARTs) to Facilitate Women’s Choice Between Oral and Long-Acting Injectable Antiretroviral Treatment for HIV: Protocols for its Development and Randomized Controlled Pilot Trial

A Patient Decision Aid (i.ARTs) to Facilitate Women’s Choice Between Oral and Long-Acting Injectable Antiretroviral Treatment for HIV: Protocols for its Development and Randomized Controlled Pilot Trial

A Patient Decision Aid (i.ARTs) to Facilitate Women’s Choice Between Oral and Long-Acting Injectable Antiretroviral Treatment for HIV: Protocols for its Development and Randomized Controlled Pilot Trial

Authors of this article:

Morgan M Philbin1 Author Orcid Image ;   Tara McCrimmon1 Author Orcid Image ;   Victoria A Shaffer2 Author Orcid Image ;   Deanna Kerrigan3 Author Orcid Image ;   Margaret Pereyra1 Author Orcid Image ;   Mardge H Cohen4 Author Orcid Image ;   Oluwakemi Sosanya5 Author Orcid Image ;   Anandi N Sheth6 Author Orcid Image ;   Adaora A Adimora7 Author Orcid Image ;   Elizabeth F Topper8 Author Orcid Image ;   Aadia Rana9 Author Orcid Image ;   Bani Tamraz10 Author Orcid Image ;   Lakshmi Goparaju11 Author Orcid Image ;   Tracey E Wilson12 Author Orcid Image ;   Maria Alcaide13 Author Orcid Image
Article Authors Cited by (12) Tweetations (2) Metrics

Journals

  1. Paudel K, Gupta S, Gautam K, Wickersham J, Khati A, Azwa I, Ha T, Shrestha R. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. Journal of Community Health 2023;48(3):513 View
  2. O'Shea J, Cholli P, Heil E, Buchacz K. Considerations for long-acting antiretroviral therapy in older persons with HIV. AIDS 2023;37(15):2271 View
  3. Kennedy C, Zhao T, Vo A, Nakubulwa R, Nabakka P, Jackson J, Rosen J, Chang L, Reynolds S, Quinn T, Nakigozi G, Kigozi G, Kagaayi J, Nalugoda F, Ddaaki W, Grabowski M, Nakyanjo N. High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda. AIDS Patient Care and STDs 2023;37(6):316 View
  4. Goebel M, Guajardo E, Giordano T, Patel S. The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch. Current HIV/AIDS Reports 2023;20(5):271 View
  5. Rodriguez Gonzalez H, Volcan A, Castonguay B, Carda-Auten J, Ruiz C, Peretti M, Suarez A, Kerrigan D, Wohl D, Barrington C. “What Is the Benefit?”: Perceptions and Preferences for Long-Acting Injectable Antiretroviral Therapy Among People Living With HIV. AIDS Education and Prevention 2023;35(6):467 View
  6. Dubé K, Perez-Brumer A, Patel H, Zhou C, Dee L, Graham G, Meanley S, Philbin M. “This Is Actually a Really Unique Moment in Time”: Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions—A Qualitative Interview Study in the United States. AIDS Research and Human Retroviruses 2024;40(8):455 View
  7. Dubé K, Perez-Brumer A, Patel H, Zhou C, Dee L, Graham G, Meanley S, Philbin M. “This Is Actually a Really Unique Moment in Time”: Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions—A Qualitative Interview Study in the United States. AIDS Research and Human Retroviruses 2024;40(8):455 View
  8. Erguera X, Koester K, Diaz Tsuzuki M, Dance K, Flores R, Kerman J, McNulty M, Colasanti J, Collins L, Montgomery E, Johnson M, Sauceda J, Christopoulos K. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States. AIDS and Behavior 2024;28(7):2226 View
  9. Manghani P, Monroe A, Castel A, Kumar P, Phunmongkol J, Denyer R, O’Connor L. Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV. Open Forum Infectious Diseases 2024;11(5) View
  10. McCrimmon T, Collins L, Pereyra M, Platamone C, Perez-Brumer A, Shaffer V, Kerrigan D, Sheth A, Cohen M, Hanna D, Ramirez C, Gange S, Rana A, Tamraz B, Goparaju L, Wilson T, Alcaide M, Philbin M. Likelihood of trying long-acting injectable antiretroviral therapy (LAI ART) among women with HIV in nine sites across the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 2024 View
  11. Haser G, Balter L, Gurley S, Thomas M, Murphy T, Sumitani J, Leue E, Hollman A, Karneh M, Wray L, Washington M, Corbin-Johnson D, Condra A, Niles-Carnes L, Smith B, Armstrong W, Kalokhe A, Colasanti J, Collins L. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South. AIDS Research and Human Retroviruses 2024;40(12):690 View
  12. Christopoulos K, Smith M, Pareek P, Dawdani A, Erguera X, Dance K, Walker R, Grochowski J, Mayorga‐Munoz F, Hickey M, Johnson M, Sauceda J, Gutierrez J, Montgomery E, Colasanti J, Collins L, McNulty M, Koester K. Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics. Journal of the International AIDS Society 2024;27(11) View